Dose-Intense Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies

Trial Profile

Dose-Intense Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Bendamustine; Fludarabine; Rituximab
  • Indications Lymphoid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 15 Feb 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
    • 15 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top